Published Erratum
doi: 10.1038/s41573-019-0023-6.
Publisher Correction: The current state and future directions of RNAi-based therapeutics
Affiliations
- PMID: 30886427
- DOI: 10.1038/s41573-019-0023-6
Item in Clipboard
Published Erratum
Publisher Correction: The current state and future directions of RNAi-based therapeutics
Nat Rev Drug Discov.
2020 Apr.
Abstract
The use of the names for patisiran has been made consistent throughout the article in line with the journal style and typographical errors have been corrected.
Erratum for
-
The current state and future directions of RNAi-based therapeutics.Nat Rev Drug Discov. 2019 Jun;18(6):421-446. doi: 10.1038/s41573-019-0017-4. Nat Rev Drug Discov. 2019. PMID: 30846871 Review.
Similar articles
-
Author Correction: The current state and future directions of RNAi-based therapeutics.Nat Rev Drug Discov. 2020 Apr;19(4):290. doi: 10.1038/s41573-019-0027-2. Nat Rev Drug Discov. 2020. PMID: 31019276
-
The current state and future directions of RNAi-based therapeutics.Nat Rev Drug Discov. 2019 Jun;18(6):421-446. doi: 10.1038/s41573-019-0017-4. Nat Rev Drug Discov. 2019. PMID: 30846871 Review.
-
Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis.J Neurol. 2020 Mar;267(3):703-712. doi: 10.1007/s00415-019-09602-8. Epub 2019 Nov 14. J Neurol. 2020. PMID: 31728713 Free PMC article. Clinical Trial.
-
Publisher Correction: Surface-wetting characterization using contact-angle measurements.Nat Protoc. 2019 Jul;14(7):2259. doi: 10.1038/s41596-018-0047-0. Nat Protoc. 2019. PMID: 30087432
-
Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis.Neurodegener Dis Manag. 2019 Feb;9(1):5-23. doi: 10.2217/nmt-2018-0033. Epub 2018 Nov 27. Neurodegener Dis Manag. 2019. PMID: 30480471 Review.
Cited by
-
Expanding RNAi to Kidneys, Lungs, and Spleen via Selective ORgan Targeting (SORT) siRNA Lipid Nanoparticles.Adv Mater. 2024 Aug;36(35):e2313791. doi: 10.1002/adma.202313791. Epub 2024 Jul 8. Adv Mater. 2024. PMID: 38973655 Free PMC article.
-
Message in hand: the application of CRISPRi, RNAi, and LncRNA in adenocarcinoma.Med Oncol. 2022 Jul 14;39(10):148. doi: 10.1007/s12032-022-01727-7. Med Oncol. 2022. PMID: 35834017 Review.
-
Concurrent silencing of TBCE and drug delivery to overcome platinum-based resistance in liver cancer.Acta Pharm Sin B. 2023 Mar;13(3):967-981. doi: 10.1016/j.apsb.2022.03.003. Epub 2022 Mar 12. Acta Pharm Sin B. 2023. PMID: 36970197 Free PMC article.
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
